ALFA Finder| Revenue growth | FY26: 7.6% YoY. Guidance FY27: 34% growth to ₹530cr. |
|---|---|
| Margins | EBITDA margins rising towards 24% as branded/export mix increases. |
| Order book | 50% of H1 FY27 export orders already in hand. |
| Demand visibility | Strong; tenders awarded in March 2026 for supply starting Q1 FY27. |
| Management confidence | High; citing visibility from awarded export tenders and IVF synergies. |
Growth
FY26 Revenue grew 7.6% to ₹396cr. EBITDA rose 12.8% to ₹86.85cr; margins improved to 22.57%.
Outlook
Guided FY27 revenue of ₹530cr (34% growth) and 24% EBITDA margin. Vision 2030 target: ₹900cr revenue.
Risks
Export tender delays (impacted FY26 by ₹25cr) and pricing pressure on Carboplatin in India.
Earnings Call filed with NSE, NSE: BETA. Summary written with AI assistance from the document.
Beta Drugs Ltd: key numbers
- Share price
- ₹1,878.30
- Market cap
- ₹2,082 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 40.1×Sector 43.8×
- Promoter holding
- 58.91%-0.19% QoQ
- FII holding
- 1.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Other Announcement
Beta Drugs filed its sixth monitoring agency report for the quarter ended 30 September 2026. Brickwork Ratings reported no deviation in utilisation of the preferential issue proceeds.
Beta Drugs Other Announcement
Beta Drugs Limited submitted its quarterly Statement of Deviation or Variation for the preferential issue proceeds, confirming no deviation from the stated objects.
Beta Drugs Earnings Call Transcript: Key Takeaways
Management projects a 20-25% growth trajectory despite Q2 bottlenecks. Recent acquisitions and niche oncology focus underpin expansion strategy.
- Call
- Guides 25% growth
Beta Drugs Investor Presentation: Key Takeaways
Beta Drugs reported H1 FY27 revenue of INR 263 Cr with EBITDA margins expanding to 23.2%. The firm is transitioning from a CMO to a branded specialty oncology powerhouse.
Beta Drugs Q2 FY27 Results: Net Profit ₹18.55 Cr, Up 51.8% YoY
Beta Drugs Ltd reported revenue from operations of ₹137.5 Cr (+33.0% YoY) and net profit of ₹18.55 Cr (+51.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.55 Cr · +51.8% YoY
Beta Drugs Board Meeting Date
Beta Drugs Limited notified the exchange of a board meeting scheduled for 22-Oct-2026 to consider quarterly financial results. The trading window closure was also intimated.